^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

DKY709

i
Other names: DKY709, DKY 709, DKY-709
Associations
Trials
Company:
Novartis
Drug class:
IKZF2 protein degrader
Associations
Trials
1m
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Mar 2026 --> Oct 2026 | Trial primary completion date: Mar 2026 --> Oct 2026
Trial completion date • Trial primary completion date
|
spartalizumab (PDR001) • DKY709
4ms
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2025 --> Mar 2026
Trial completion date
|
spartalizumab (PDR001) • DKY709
6ms
Discovery of a Novel Series of iso-Indolinone-Based Glutarimides as Highly Efficacious and Selective IKZF2 Molecular Glue Degraders. (PubMed, J Med Chem)
We developed a novel series of iso-indolinone-based glutarimides, identifying compound 55 as a potent, selective IKZF2 degrader with >90% Dmax in Jurkat cells, outperforming benchmarks DKY709 and PVTX-405. PK/PD studies confirmed profound, persistent IKZF2 degradation in mouse spleen and thymus after a single oral dose. As a promising early-stage tool, 55 provides a foundation for further preclinical evaluation in cancer immunotherapy.
Journal
|
IKZF2 (IKAROS family zinc finger 2)
|
DKY709
8ms
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2025 --> Dec 2025 | Trial primary completion date: Sep 2025 --> Dec 2025
Trial completion date • Trial primary completion date
|
spartalizumab (PDR001) • DKY709
11ms
Crosslinking Profiling of Molecular Glue Degrader-Induced E3 Ligase Interactome to Expand Target Space. (PubMed, Angew Chem Int Ed Engl)
Our approach presents an efficient and robust strategy for identifying neo-substrates recruited to cereblon E3 ligase by the known degraders CC-885 and DKY709, offering valuable insights for clinical evaluation and significantly expanding their target space. Moreover, we developed two novel MG degraders with potent anti-proliferative effects on cancer cells, and application of our method identified neo-substrates, revealing a previously unrecognized target landscape and advancing our understanding of E3 ligase-neo-substrate interactions. Overall, our study provides a powerful tool for neo-substrate identification and expanding target space of E3 ligase, opening new opportunities for developing next-generation MG degraders to address the clinical challenge of undruggable targets.
Journal
|
CRBN (Cereblon)
|
DKY709
11ms
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2025 --> Sep 2025 | Trial primary completion date: May 2025 --> Sep 2025
Trial completion date • Trial primary completion date
|
spartalizumab (PDR001) • DKY709
1year
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Feb 2025 --> May 2025 | Trial primary completion date: Feb 2025 --> May 2025
Trial completion date • Trial primary completion date
|
spartalizumab (PDR001) • DKY709
over1year
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial primary completion date: May 2025 --> Dec 2024
Trial primary completion date • Combination therapy • Metastases
|
spartalizumab (PDR001) • DKY709
over1year
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Dec 2024 --> May 2025 | Trial primary completion date: Dec 2024 --> May 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
spartalizumab (PDR001) • DKY709
over1year
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
spartalizumab (PDR001) • DKY709
almost2years
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: May 2025 --> Sep 2024 | Trial primary completion date: May 2025 --> Sep 2024
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
spartalizumab (PDR001) • DKY709
2years
Study of Safety and Efficacy of DKY709 Alone or in Combination With PDR001 in Patients With Advanced Solid Tumors. (clinicaltrials.gov)
P1, N=98, Active, not recruiting, Novartis Pharmaceuticals | Trial completion date: Apr 2024 --> May 2025 | Trial primary completion date: Apr 2024 --> May 2025
Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
spartalizumab (PDR001) • DKY709